icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
Evaluation of efficacy of sofosbuvirand simeprevir-based regimens in a real-life population of HCV patients with cirrhosis; data from the TRIO network
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Steven Flamm1, Bruce Bacon2, Douglas Dieterich3, Kris Kowdley4, Eric Lawitz5, Scott Milligan6, NaokyTsai7, and ZobairYounossi8 1Northwestern University Feinberg School of Medicine, 2Saint Louis University School of Medicine, 3Mount Sinai School of Medicine, 4Swedish Liver Center and Transplant Program, Swedish Medical Center, 5The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, 6Trio Health Analytics, 7Queens Medical Center, University of Hawaii, 8Center for Liver Diseases, Department of Medicine, InovaFairfax Hospital
AASLD: Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population - (11/10/14)